Please provide your email address to receive an email when new articles are posted on . Safety and tolerability were consistent with benralizumab’s known profile. Benralizumab is currently approved as ...

Severe eosinophilic asthma (SEA) is a debilitating respiratory condition characterized by persistent airway inflammation and high eosinophil levels, resulting in frequent exacerbations and significant ...

Treatment with twice-yearly depemokimab resulted in a significant reduction in the rate of annualized asthma exacerbations compared with placebo. The Food and Drug Administration (FDA) has approved ...

Eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg-Strauss syndrome) is typically characterized by asthma, blood and tissue eosinophilia, and small-vessel vasculitis. 1 ...

Treatment failures occurred in 74% and 45% of patients in the PRED and pooled BENRA groups, respectively, at 90 days. (HealthDay News) — Benralizumab can be used for the treatment of acute ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. 58.2% of patients experienced a clinically important ...

The FDA approved on Wednesday AstraZeneca Plc’s (NASDAQ:AZN) Fasenra (benralizumab) for eosinophilic granulomatosis with polyangiitis (EGPA), a rare, immune-mediated vasculitis (inflammation of the ...

Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based on SWIFT trials showing ...

Specific sputum markers, including higher sputum eosinophils, macrophages, and lymphocyte counts, were associated with remission after interleukin-5 (IL-5)–targeted therapy for patients with severe ...

China: Researchers have found in a new meta-analysis that mepolizumab is an effective and safe treatment for severe ...

WAYNE, Pa. and ROCKVILLE, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced that the first patient has been dosed in the company’s Phase 2 PEAK (A Phase 2, ...

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%. The findings, published today in ...